US Patent

US9867791 — Method of administering amantadine prior to a sleep period

Method of Use · Assigned to Adamas Pharma LLC · Expires 2030-12-02 · 5y remaining

Vulnerability score 68/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects methods of administering amantadine at night to reduce sleep disturbances in patients taking the medication.

USPTO Abstract

Methods of nighttime administration of amantadine to reduce sleep disturbances in patient undergoing treatment with amantadine are described, as well as compositions of extended release amantadine that are suitable for nighttime administration.

Drugs covered by this patent

amantadine-hydrochloride (AMANTADINE HYDROCHLORIDE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2106`	—	amantadine-hydrochloride
`U-2106`	—	amantadine-hydrochloride

Patent Metadata

Patent number: US9867791
Jurisdiction: US
Classification: Method of Use
Expires: 2030-12-02
Drug substance claim: No
Drug product claim: No
Assignee: Adamas Pharma LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.